Pharmaceutical companies must diversify their business models away from selling products, and urgently focus sales strategies on expanding revenues from emerging markets, a new study from strategy consultants Roland Berger reveals.
The report, Pharma at the Crossroads, is the result of research among 50 senior decision makers in the world's leading pharmaceutical firms. The research paints a picture of an industry undergoing fundamental change. This is being driven by new registration procedures and fiercer price competition due to the restructuring of health care systems in different regions of the world.
David Stern, managing partner, Roland Berger UK, comments: "the pharmaceutical industry does not have a clear vision for the future. The answers to certain fundamental questions may make or break the players in the industry over the coming years."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze